

# 2<sup>nd</sup>

# Annual Summit Visual Inspection in Parenterals

online | September 28<sup>th</sup>– 29<sup>th</sup>, 2026

Key Speakers:

3:30pm IST / 12:00pm CET / 6:00am EST



**Chiara Sinito, CH**  
Head of AVI  
WILCO AG



**Bram Keymolen, BE**  
Co-Founder | Compliance Director  
eyetec



**Robin Van Mechelen, BE**  
Senior Process Engineer Visual  
Inspection & CCIT  
eyetec



**Brian Turnquist, USA**  
Chief Technology Officer  
Boon Logic



**Massimo Frasson, IT**  
CEO & General Manager  
Brevetti CEA s.p.a



**Srivalli Telikepalli, USA**  
Research Chemist  
National Institute of Standards  
and Technology



**Elisabeth Wagner, CH**  
Senior Lead Visual Inspection  
CSL Behring




**Callum Leonard, UK**  
Director & AVI SME  
Valisense




**Roman Mathaes, CH**  
Chief Executive Officer  
Clear Solutions Laboratories



**Roy Cherris, USA**  
Cherris-Chief Science Officer  
InQuest Science LLC



**Anthony Amato, USA**  
Amato-Product Development  
Manager  
InQuest Science LLC



**Oliver Germershaus, CH**  
Professor for Pharmaceutical  
Technology of Macromolecular Drugs  
FHNW



# 2<sup>nd</sup>

Annual Summit

## Visual Inspection in Parenterals

September 28<sup>th</sup>– 29<sup>th</sup>, 2026

### Conference Overview

The **Visual Inspection in Parenterals** summit is a premier event that brings together experts from the pharmaceutical and biotechnology sectors to explore best practices, technologies and advancements in the visual inspection of parenteral products.

In 2026 the industry is moving beyond simple detection toward a holistic life-cycle approach. This conference will cover a wide range of topics, from the latest innovations in Deep Learning and Generative AI to the integration of visual inspection into broader Contamination Control Strategies (CCS). Attendees will gain insights into cutting-edge technologies, evolving GMP Annex 1 requirements and clinical case studies aimed at enhancing the accuracy of inspections while ensuring patient safety.

### Who Is It For?

The event covers key areas of product quality, regulatory compliance and manufacturing processes. The following departments would benefit from the insights shared at the conference:

- Quality Control (QC)
- Quality Assurance (QA)
- Regulatory Affairs
- Manufacturing/Production
- Research and Development (R&D)
- Engineering and Validation
- Packaging
- Supply Chain
- Product Development
- Microbiology
- Clinical Affairs
- Technical Operations

### We Will Talk About

- Regulatory & CCS: Aligning visual inspection with Annex 1 and global compendial requirements.
- The Digital Shift: Moving from manual processes to AI-driven and paperless systems.
- Management over Detection: Holistic strategies for particulate matter and characterization.
- Clinical Relevance: Determining the patient safety risks of different defect categories.
- Operational Excellence: Reducing false rejects and improving yield through advanced validation.
- Complex Products: Inspection challenges for autoinjectors, cell therapies and BFS.
- Techniques for visual inspection of container integrity in parenterals.
- Challenges of visual inspection for suspensions, emulsions and BFS parenterals.

12:00 - 12:05

 Registration

12:05 - 12:10

 Opening Address from the Organizer

## Strategy, AI, and Regulation

12:10 - 12:40

Massimo Frasson, IT  
CEO & General Manager  
Brevetti CEA s.p.a



### EU GMP Annex 22 (Draft 2025): A Compliance Framework in Inspection

- Annex 22 as the foundation for reliable, scalable, and inspectable visual systems.
- Static Model. • Explainability. • Risk-based AI Adoption.
- Quality of Data. • The Labeling Challenge.
- Synthetic Defect Injection. • AI-Assisted Annotation.
- Benefits: Increased Annotation Efficiency. • Conclusions.

12:40 - 12:50

 Short Break

12:50 - 13:20



### Digitalization and the Lifecycle Approach

- Moving toward paperless documentation and digital data integrity (ALCOA+).
- Design, validation and ongoing monitoring stages for consistent lifecycle performance.

13:20 - 13:30

 Short Break

13:30 - 14:00



### Risk-Based Validation and Sustainability

- Importance of a risk-based approach in validation to minimize downtime.
- Reducing product waste and glass loss through optimized inspection sensitivity.

14:00 - 14:10

 Short Break

14:10 - 14:40

Roman Mathaes, CH  
Chief Executive Officer  
Clear Solutions  
Laboratories



### A Roadmap for Implementation of Automated Visual Inspection for Parenteral Drug Products

- Demonstrating AVI equivalence to Manual Visual Inspection (MVI) per USP <1790> and EU GMP Annex 1.
- Defining fit-for-purpose VI test sets throughout the AVI lifecycle.
- Common implementation pitfalls and mitigation strategies.
- Optimization of false reject rates (FRR) during vision engineering.
- Product bracketing considerations for AVI systems.
- Opportunities and limitations of artificial intelligence in AVI.

14:40 - 15:00

 Break

15:00 - 15:30



### Inspector Training: The Human-Machine Interface

- Modern qualification processes and the use of Virtual Reality (VR) for training.
- Managing human factors: Fatigue, cognitive bias and physiological limits.

15:30 - 15:40

 Short Break

15:40 - 16:10



Elisabeth Wagner, CH  
Senior Lead Visual Inspection  
CSL Behring

CSL Behring

### Two-Stage Inspection and Rejection Strategies

- Using two-stage systems to improve defect detection and reduce the risk of overlooked defects.
- Analyzing the «grey zone» to minimize false rejections and maximize yield.

16:10 - 16:20

 Short Break

16:20 - 16:50



Robin Van Mechelen, BE  
Proces Engineer Visual  
Inspection  
eyetec

 eyetec  
compliant pharma solutions

### AI and generative data for Visual Inspection

- AI usage in Visual Inspection.
- Annex 22: regulatory requirements.
- Practice examples on AI usage in Visual Inspection.

16:50 - 17:00

 Organizer's closing remarks and end of day one

12:00 - 12:05

 Registration

12:05 - 12:10

 Opening Address from the Organizer

## Particles, Integrity and Clinical Risk

12:10 - 12:40



### Clinical Risk and Defect Classifications

- Categorizing defects based on patient safety risk rather than just appearance.
- Standardizing classifications (critical, major, minor) across global manufacturing sites.

12:40 - 12:50

 Short Break

12:50 - 13:20



Bram Keymolen, BE  
Co-Founder | Compliance  
Director  
**eyetec**



### Holistic Particulate Matter Management

- Main sources of particulate matter in manufacturing of sterile product (with real life examples).
- Strategies for particulate matter monitoring.
- Strategies for particulate matter avoidance.
- Product lifecycle management: linking identification to qualification.

13:20 - 13:30

 Short Break

13:30 - 14:00



Srivalli Telikepalli, USA  
Research Chemist  
**NIST**



### Development of New Visible Particle Reference Material for Biopharmaceutical Advancement (tentative)

- Particle Based Reference Materials in Development.
- Need for Visible Particle Reference Material.
- Development and Applications of Visible Particle Reference Material.

14:00 - 14:10

 Short Break

14:10 - 14:40



Oliver Germershaus, CH  
Professor for Pharmaceutical  
Technology of  
Macromolecular Drugs  
**Fachhochschule  
Nordwestschweiz FHNW**



### Precision-Designed 3D Printed Inherent Particle Mimics for Visual Inspection System Qualification

- Conventional standards (polystyrene spheres, glass beads) poorly represent real parenteral particles in refractive index, morphology, and suspension behavior.
- Two-photon 3D printing enables precise tuning of particle size, shape, and optical properties to create more realistic standards.
- Standards can be tailored to mimic product-specific particles such as protein aggregates or cell clumps.

14:40 - 15:00

 Break

15:00 - 15:30

Brian Turnquist, USA  
Chief Technology Officer  
Boon Logic



**boon**

### Automated Inspection of Difficult-to-Inspect Products

- Why DIPs are a challenge for AVI.
- Human cognition and defect detection in DIPs.
- Applying high-dimensional unsupervised machine learning to replicate human visual cognition and inspect DIPs.

15:30 - 15:40

 Short Break

15:40 - 16:10



### Test Set Creation and Standard Reference Kits

- Best practices for creating and maintaining stable, reproducible defective test sets.
- Using 3D printing and precision seeding to simulate realistic defects.

16:10 - 16:20

 Short Break

16:20 - 16:50



### The Modern Knapp Test: Sensitivity and Limits

- Applications of the Knapp test for comparing human vs. machine performance.
- Determining the «threshold of detection» and the future of Digital Twins in sensitivity testing.

16:50 - 17:00

 Organizer's closing remarks and end of day two



**Chiara Sinito**  
Head of AVI  
WILCO AG



Dr. Chiara Sinito obtained her PhD in Physics at the University of Bordeaux, where she specialized in the magneto-photoluminescence spectroscopy of individual semiconductor nanocrystals. As a Post-doctoral Researcher in France and in Germany, she continued to study the optical properties of semiconductor nanostructures for the realization of advanced semiconductor devices. As an Application Engineer at the Swiss company Attolight AG, she applied cathodoluminescence to the failure analysis of semiconductor-based devices for industrial customers. Since 2021 she leads the Automated Visual Inspection team at the Swiss company WILCO AG. With a team of research engineers, she develops new solutions in machine vision for the quality control of pharmaceutical products and medical devices, thus improving the manufacturing processes in the pharmaceutical industry. She is co-leader of the A3P (Association Produits Propres et Parénteraux) interest group on Visual Inspection, where she contributes to the harmonization of Visual Inspection practice across the pharmaceutical industry.



**Brian Turnquist**  
Chief Technology Officer  
Boon Logic



Brian Turnquist is CTO of Minneapolis AI company, Boon Logic, where he directs Boon's technical roadmap, identifies differentiated application areas for Boon's novel unsupervised machine learning technology, and develops those with his team into transformational applications in diverse fields such as pharmaceutical visual inspection, grid edge analytics, predictive analytics, cyber intrusion detection, and cognitive electronic warfare. Turnquist's PhD is in Mathematics from the University of Maryland. Prior to joining Boon Logic, he spent 20 years in neuroscience at Johns Hopkins University and was a visiting researcher at the University of Nürnberg and University of Heidelberg. Turnquist has fifteen refereed publications in neuroscience and mathematics.



**Srivali Telikepalli**  
Research Chemist  
National Institute of Standards and  
Technology



Dr. Srivali Telikepalli is a recognized expert in biopharmaceutical analytical science with more than 10 years of experience specializing in protein aggregation, particle characterization, and monoclonal antibody stability. As a Research Chemist at National Institute of Standards and Technology, she has led the development of several industry-first reference materials, including the first subvisible and visible protein-like particle standards, and supported the NIST monoclonal antibody reference material, which are now widely used across the biopharmaceutical industry for analytical benchmarking and quality control. Dr. Telikepalli currently leads major cross-industry collaborations involving global biopharmaceutical companies to advance standards for protein aggregation and visual inspection methodologies, helping shape emerging regulatory and industry best practices. An internationally invited speaker and thought leader in biologics stability and analytical characterization, she has authored numerous high-impact publications and received multiple honors from the U.S. Department of Commerce for her contributions to measurement science and biopharmaceutical standards.



**Bram Keymolen**  
Co-Founder | Compliance Director  
eyetec



Bram Keymolen, a Qualified Person with a master's degree in Industrial Pharmacy from the University of Antwerp, brings over 20 years of GMP experience in roles spanning qualification, validation, QA, and QP. His extensive background includes key positions in biotech companies, startups, corporations, and university hospitals, with a strong focus on sterile production. In 2011, Bram founded eyetec, specializing in Visual Inspection (VI) and Container Closure Integrity Testing (CCIT) under GMP standards. Together with Gunther Coenen, his co-founder at eyetec, who has a strong background in pharmaceutical manufacturing, they offer a unique blend of production, engineering, and compliance expertise. A key differentiator of eyetec is its expertise in developing specialized Visual Inspection Test Sets, including Particle Test Samples (PTS) and container defects, designed to validate both manual and automated inspection systems. Furthermore, eyetec offers CCIT samples, known as Leak Test Samples (LTS), which serve as certified positive controls with precisely calibrated leak defects. eyetec also sells GMP and lab equipment and provides critical after-sales support, including maintenance, and calibration for GMP and lab equipment.



**Massimo Frasson**  
CEO & General Manager  
Brevetti CEA s.p.a



Massimo Frasson holds a master's degree in mechanical engineering and has a successful career in the automation industry. He began his journey with Brevetti C.E.A. in 2000 as the Mechanic Systems Design Manager and progressively assumed more significant roles. In 2007, he played a pivotal role in Brevetti C.E.A.'s restructuring and the introduction of new vision technologies. Simultaneously, he led a department focused on pharmaceutical process analysis using artificial vision systems and neural algorithms. In 2010, Mr. Massimo Frasson took on the responsibility for the entire operations process and was appointed General Manager in February 2014. His leadership and dedication led to his promotion to CEO in 2019. Today, he continues to drive Brevetti C.E.A.'s growth and development with his extensive industry knowledge and commitment to excellence.



**Elisabeth Wagner**  
Senior Lead Visual Inspection  
CSL Behring



Elisabeth Wagner is the Senior Lead Visual Inspection at CSL Behring. She joined the company in 2017 and held roles of increasing responsibility in visual inspection. Elisabeth was involved in the qualification of an automated inspection system for Albumin in molded glass containers and led the production team before the ramp-up to routine production. In 2021, she moved to the global function. As the business process owner for this area, Elisabeth is involved in internal and external tech transfer projects and leading the global visual inspection program within the CSL network. She is the main responsible for standardization of processes and implementing the best practice at all sites.



**Roman Mathaes**  
Chief Executive Officer  
Clear Solutions Laboratories



Roman Mathaes is CEO of Clear Solutions Laboratories and a recognized expert in visual inspection and particle contamination control for injectable medicines. Previously, he held leadership roles at Roche/Genentech and served as Head of Pharmaceutical Services at Lonza, supporting global pharmaceutical development and manufacturing.



**Callum Leonard**  
Director & AVI SME  
Valisense



Founder of Valisense, a consulting firm focused on Automated Visual Inspection (AVI) implementation and optimization in regulated manufacturing. Previously involved in early-stage software startup, contributing to product development, system architecture, and scaling technical solutions. Background in Computer Science and software engineering. Leads end to end deployment of AVI systems, from requirements definition through validation and production rollout.



**Roy Cherris**  
Cherris-Chief Science Officer  
InQuest Science LLC



Mr. Cherris has over 40 years of Quality Assurance experience. He is a founding member and Managing Partner of Bridge Associates International. He is also Chief Science Officer of InQuest Science. Mr. Cherris formerly served as the head of Microbiology Laboratories for Hoechst Marion Roussel and Aventis Pharmaceuticals. He is a well respected expert in the field of visual inspection systems and investigative microscopy for particle source identification and mitigation. His technical expertise includes visual Inspection, investigative microscopy, aseptic manufacturing, sterilization processes, environmental monitoring, microbiological testing, medical devices, laboratory and process development, as well as the qualification of equipment, facilities, and instrumentation. He has been certified by the New Jersey Pharmaceutical Quality Control Association in GxP, Good Manufacturing Practices. Mr. Cherris has worked internationally throughout the Americas, Australia, Europe and Asia. Mr. Cherris has a B.S.c. degree in Life Sciences with concentration in Microbiology and has studied forensic microscopy extensively at the McCrone Research Institute in Chicago. His current publication is the technical book titled "Visual Inspection and Particulate Control" 2016, Davis Healthcare International Publishing. Mr. Cherris has served as a member of the PDA task force on Visual Inspection since 1998, and has been an active member of the USP Expert Panel for Visual Inspection of parenterals since 2009. His professional activities have included various technical committees in ASQ, ASTM, ISPE, PhRMA(PMA), PDA, American Society for Microbiology, Institute of Environmental Sciences, and the United States Pharmacopeia.



**Anthony Amato**  
Amato-Product Development Manager  
InQuest Science LLC



Mr. Amato joined InQuest Science in September 2021 as our Product Development Manager. Mr. Amato is responsible for the organization strategies through the effective direction and management of resources, while being accountable for the business strategies, functional or operational areas processes or programs. Responsible and accountable for managing, setting direction and deploying resources on varying projects. Participating in organization-wide projects, while providing guidance and expertise on an as needed basis. Design, develop, modify, adapt and implement solutions for information technology needs through new and existing applications, systems architecture and applications infrastructure.



**Oliver Germershaus**  
Professor for Pharmaceutical Technology of  
Macromolecular Drugs  
Fachhochschule Nordwestschweiz FHNW



Oliver Germershaus is Professor of Pharmaceutics of Macromolecular Drugs and Head of the Institute of Pharmaceutical Technology and Biotechnology at the University of Applied Sciences Northwestern Switzerland. His research focus areas include formulation and processing of biologics, development of drug delivery systems, and parenteral packaging and device development. In recent years, he has placed special emphasis on developing novel particle standards designed to match the appearance and behavior of inherent particles. Germershaus is co-founder and chief scientific officer of Partiris, a Swiss startup that focuses on developing and manufacturing specialized pharmaceutical standard materials, such as particle standards for manual and automatic visual inspection.



**Robin Van Mechelen**  
Process Engineer Visual Inspection & CCIT  
Eyetec



Robin Van Mechelen is a Senior Process Engineer Visual Inspection & CCIT at Eyetec, specializing in Visual Inspection and Container Closure Integrity Testing (CCIT) within the pharmaceutical industry. With over eight years of experience, he has developed strong expertise in automated, semi-automated and manual visual inspection processes, with a particular focus on qualification/validation and performance optimization. He has played a key role in the implementation and qualification of Automated Visual Inspection (AVI) systems across multiple pharmaceutical manufacturing sites, supporting robust inspection strategies and alignment with regulatory expectations. He holds a Master's degree in Industrial Engineering with a specialization in automation.

# Registration Form

SUMMIT NAME:

REGISTRATION DATE:

COUPON CODE:



E-mail this form to [register@uventia.com](mailto:register@uventia.com)  
Upon receiving the registration form, we will send you an invoice for payment and all the necessary information.

PACKAGE NAME	2 Days Ticket + Recording - €595 per person	1 Day Ticket + Recording - €415 per person	2 Days Recording - €495
	Full access to the 2 days online event.	Full access to the 1 day online event.	Recording of 2 days event sessions.
	Digital certificate, List of participants.	Digital certificate, List of participants.	List of participants.
	Recording of 2 days event sessions, PDF.	Recording of 1 day event sessions, PDF.	PDF presentations.

## 1<sup>st</sup> Attendee

Full Name:  
Job Title:  
Company:  
Country: Phone:  
Email:

## 2<sup>nd</sup> Attendee

Full Name:  
Job Title:  
Company:  
Country: Phone:  
Email:

## 3<sup>rd</sup> Attendee

Full Name:  
Job Title:  
Company:  
Country: Phone:  
Email:

## 4<sup>th</sup> Attendee

Full Name:  
Job Title:  
Company:  
Country: Phone:  
Email:

## INVOICE DETAILS

Full Name:  
Job Title:  
Company:  
Country: City:  
Address:  
Postcode: Phone:  
EU VAT #:  
Email:

## PAYMENT METHOD

Bank Transfer: Credit Card: PayPal:

Signature: «I agree to be bound by Terms and Conditions of registration»

## TERMS & CONDITIONS

### REGISTRATION & PAYMENT

Onsite events. We will process your application after receiving the signed registration form. We will send you a registration confirmation and invoice with payment instructions within one business day. Payment is due within 10 working days from the date of invoice issuance. Payment can be made by bank transfer or credit card. The registration fee includes participation in all (available) meetings, lunches and refreshments, participation in social activities during the event, and conference documentation packages. The registration fee does not include travel and hotel accommodation. Uventia is not responsible for any additional bank charges related to payment.

### CANCELLATION & SUBSTITUTION POLICY

Virtual webinars. Cancellation is required in writing only. If you cancel within 24 hours after registering for the webinar, the registration fee can be refunded in full. Cancellation after this time will incur the full registration fee. If recording is possible, registered representatives who cannot access the live webinar will receive the recording after the webinar or presentation slides. Non-attendance to the live webinar will still be charged the full registration fee. If payment is received and recording access is provided, there will be no refund. The delegate pass cannot be transferred to another webinar and no substitutions possible.

### EVENT CHANGES & CANCELLATIONS

Virtual Webinars. If we need to change the webinar program, postpone the webinar, cancel or replace the speaker (for example, the speaker suddenly falls ill), the reimbursement of the registration fee is not possible. However, if the event was cancelled, the delegate has the right to refund the registration fee.

### DATA PROTECTION

The personal information provided by you will be held in the Uventia database. It may be used to inform you about other Uventia products and services. Unless you click here, your details may be made available to third parties for marketing purposes. For data update please write to [database@uventia.com](mailto:database@uventia.com).

SPONSORSHIP PACKAGES	Speaking €1195	Bronze €1795	Silver €2195	Gold €2595
Number of passes included	1	2	3	4
Speaking slot	30 min	30 min	30 min	30 min
Workshop slot				60 min
Advertisement in the agenda		¼ page	½ page	1 page
Materials distribution		◇	◇	◇
Discount for additional passes	10%	20%	25%	30%
Logo in the agenda	◇	◇	◇	◇
Logo on the event webpage	◇	◇	◇	◇
Recognition on our social channels		◇	◇	◇
Opening and closing speech				◇
Chairman role				◇
Recognition in chairman's opening address		◇	◇	◇